TY - JOUR T1 - IL-6: To immunity and beyond JF - Considerations in Medicine JO - Considerations Med SP - 19 LP - 23 DO - 10.1136/conmed-2018-000004 VL - 2 IS - 1 AU - Ernest H Choy AU - Simon A Jones AU - Daniel Aletaha AU - Tsutomu Takeuchi AU - Iain McInnes AU - Josef Smolen Y1 - 2018/11/01 UR - http://considerations.bmj.com/content/2/1/19.abstract N2 - Interleukin (IL)−6 inhibition has been approved for the treatment of rheumatoid arthritis, systemic juvenile arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, and, in some countries, Castleman’s disease. IL-6 has also been implicated in several non-rheumatoid arthritis inflammatory and immune conditions such as systemic sclerosis, vasculitides, systemic lupus erythematous, and psoriatic arthritis. In orphan diseases, such as systemic sclerosis, which are associated with significant morbidity and mortality and for which there are no approved treatments, IL-6 inhibition may offer a promising treatment strategy. It is also becoming clear that IL-6 may have an important role not only in inflammatory and immune diseases but also in non-immune mediated diseases such as endogenous depression and depression associated with chronic inflammatory conditions. Several studies have explored the effect of IL-6 pathway inhibition in Crohn’s disease and adult-onset Still’s disease, suggesting that IL-6 may be important in their pathogenesis. ER -